Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Zinc Sulfate→

Zinc Sulfate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7733-02-0
Molecular formula
O4SZn
Molecular weight
161.45 g/mol
Drug class
Essential trace elementzinc replacement and supplementation
Mechanism of action
Zinc is an essential divalent cation and cofactor for numerous enzymes and transcription factors involved in nucleic-acid synthesis, protein synthesis, immune function, cell division, wound healing and epithelial integrity. Zinc salts dissociate to provide zinc; counter-ions affect elemental zinc content and formulation, not the core biological target.
Indications / reported uses
  • Prevention and treatment of zinc deficiency
  • Nutritional supplementation when intake or absorption is inadequate; route, elemental dose and product-authorised claims depend on formulation and jurisdiction

Sources: NIH Office of Dietary Supplements — Zinc fact sheet · WHO — Zinc supplementation in management of diarrhoea

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Zinc Sulfate Environmental Risk Assessment (ERA) (the Zinc Sulfate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.